The Effect of Different Dosages of Solute Clearance on Outcome in Twice Weekly Hemodialysis Patients

Sponsor
Shanghai Jiao Tong University School of Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT00906555
Collaborator
(none)
400
1
2
36
11.1

Study Details

Study Description

Brief Summary

Adequacy of solute clearance makes a profound impact on clinical outcome in maintenance hemodialysis patients. Thus far, guidelines on the target of solute clearance (Kt/V or URR) are based on patients with three dialysis sessions per week. However, quite a few patients have their dialysis sessions twice per week in China. The dialysis target of solute clearance in this population remains to be elucidated. The aim of this study was to explore the optimum target solute clearance (Kt/V or URR) in maintenance hemodialysis patients with two dialysis sessions per week. Two groups of hemodialysis patients with different Kt/V (1.2 ≤ Kt/V < 1.7 versus Kt/V ≥ 1.7) will be followed until 96 weeks in this prospective, randomized, multi-center, interventional study.

Condition or Disease Intervention/Treatment Phase
  • Procedure: modification of hemodialysis parameters on dialysis machine
Phase 4

Detailed Description

This is a prospective, randomized, multi-center intervention study. 400 maintenance hemodialysis patients with twice dialysis sessions per week will be enrolled into the study. All the patients have their baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7). After treatment intervention, the patients will be randomized to two groups according to their different Kt/V (1.2 ≤ Kt/V < 1.7 vs. Kt/V ≥ 1.7), then the patients will be regularly followed up at baseline, 12 weeks, 24 weeks, 48 weeks, 72 weeks and 96 weeks. Clinical outcomes such as mortality, complications and life quality between the two groups will be investigated.

Study Design

Study Type:
Interventional
Actual Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Different Dosages of Solute Clearance on Outcome in Twice Weekly Hemodialysis Patients-A Prospective, Randomized, Multi-center Intervention Study
Study Start Date :
Jun 1, 2009
Actual Primary Completion Date :
Jun 1, 2012
Actual Study Completion Date :
Jun 1, 2012

Arms and Interventions

Arm Intervention/Treatment
No Intervention: 1

hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7)

Experimental: 2

Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.

Procedure: modification of hemodialysis parameters on dialysis machine
Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.

Outcome Measures

Primary Outcome Measures

  1. clinical outcome including mortality and morbidity [2 years]

Secondary Outcome Measures

  1. complications including cardiovascular disease, nutritional and inflammation status, calcium and phosphorus level, anemia and life quality [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients undergoing maintenance hemodialysis for more than 12 weeks were included in the study.

  2. The patients have their dialysis sessions twice weekly and have baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7).

  3. Age from 18 to 80, male or female.

  4. Patients have long term vascular access.

Exclusion Criteria:
  1. Patients with an expected survival less than 12 months.

  2. Without informed consent.

  3. Unstable organ disease such as uncurable cancer,active inflammation disease and mental disease.

  4. Patients with an expected follow up less than 48 weeks,such as planned kidney transplant.

  5. Other conditions regarded as unsuitability by investigator, such as pregnancy, alcohol or drug indulgence. A dry weight more than 90 kg is also excluded in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Renji Hospital, Shanghai Jiao Tong University school of medicine Shanghai China 200001

Sponsors and Collaborators

  • Shanghai Jiao Tong University School of Medicine

Investigators

  • Principal Investigator: Jiaqi Qian, MD, RenJi Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Aiwu Lin, Vice Director, Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:
NCT00906555
Other Study ID Numbers:
  • 08dz1900501-a
First Posted:
May 21, 2009
Last Update Posted:
Oct 13, 2016
Last Verified:
Oct 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No

Study Results

No Results Posted as of Oct 13, 2016